SD

Souvick Dey

Active Director Additional Director DIN 11102128
DIN 11102128 First appointment Jun 2025 Primary industry Paper
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jun 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Souvick Dey

Data last updated:

Souvick Dey is an Additional Director at Genifloz Pharmacon Private Limited (since 2025). The company operates in Paper.

DIN 11102128
Primary Designation Additional Director
Industry Paper
First Appointment 09 Jun 2025
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Genifloz Pharmacon Private Limited U21001WB2025PTC276443
Additional Director09 Jun 20252025Active

Board colleagues of Souvick Dey

Directorship timeline

Open interactive timeline →
Genifloz Pharmacon Private Limited
Premium access

Shareholding and investment profile for Souvick Dey

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Souvick Dey

Souvick Dey currently holds 1 directorship: Genifloz Pharmacon Private Limited (Additional Director, since 09 Jun 2025).

Souvick Dey was first appointed on 09 Jun 2025 as Additional Director at Genifloz Pharmacon Private Limited.

The current boards of Souvick Dey's companies include Manjulika Sardar (Genifloz Pharmacon Private Limited), Prasenjit Goswami (Genifloz Pharmacon Private Limited), Quazi Mowaz Ahmed (Genifloz Pharmacon Private Limited), Siddhartha Sankar Roy (Genifloz Pharmacon Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available